NEULAND LABORATORIES
|
The Current P/E Ratio of NEULAND LABORATORIES is 50.23.
Share Price | ₹11,768.4 | Feb 14,2025 |
Market Cap | ₹15,063.6 Cr | |
Earnings-TTM | ₹299.9 Cr | TTM-Consolidated Results |
Price/Earnings | 50.23x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NEULAND LABORATORIES
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹15,063.6 Cr] as on Feb 14,2025
(/) Earnings [ ₹299.9 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 50.23x ]
Thus, for NEULAND LABORATORIES , the investors are currently willing to pay 50.23 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NEULAND LABORATORIES !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NEULAND LABORATORIES over the last five years.
Historical PE (Price/Earnings) ratio chart of NEULAND LABORATORIES
PE Ratio Performance Analysis for NEULAND LABORATORIES
- NEULAND LABORATORIES 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 23.45x.
- NEULAND LABORATORIES 's operated at median p/e ratio of 22.43x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NEULAND LABORATORIES 's p/e ratio peaked in Mar2021 at 33.22x.
- NEULAND LABORATORIES 's p/e ratio hit its five-year low in Mar2023 of 14.12x.
How does NEULAND LABORATORIES 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NEULAND LABORATORIES | 299.86 | 50.23 | 15,063.6 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,486.00 | 35.61 | 409,003.0 |
CIPLA LTD | 5,000.43 | 23.56 | 117,835.0 |
DR REDDYS LABORATORIES LTD | 5,428.60 | 18.38 | 99,784.6 |
ZYDUS LIFESCIENCES LTD | 4,591.80 | 19.76 | 90,722.1 |
DIVIS LABORATORIES LTD | 2,067.00 | 74.96 | 154,939.0 |
MANKIND PHARMA LTD | 2,050.73 | 48.22 | 98,888.9 |
TORRENT PHARMACEUTICALS LTD | 1,862.00 | 54.74 | 101,923.0 |
LUPIN LTD | 2,892.10 | 31.07 | 89,860.6 |
AUROBINDO PHARMA LTD | 3,500.25 | 18.75 | 65,619.0 |
ABBOTT INDIA LTD | 1,334.46 | 44.36 | 59,198.5 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NEULAND LABORATORIES 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 18.38x |
Max industry PE | 74.96x |
Median industry PE | 35.61x |
Average industry PE | 38.15x |
You may also like the below Video Courses